News | September 27, 2024
Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress
The company will also share results in two additional posters for deuruxolitinib
The company will also share results in two additional posters for deuruxolitinib
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
ALS patients experience neuroinflammation and rapid neurodegeneration
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
New Phase II data show vast majority of patients experiencing no relapses or disability progression
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Subscribe To Our Newsletter & Stay Updated
